Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
about
KATs in cancer: functions and therapiesProtein lysine acetylation by p300/CBPExploration of the HIF-1α/p300 interface using peptide and Adhiron phage display technologiesHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsKCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacologyOvercoming therapeutic resistance in glioblastoma: the way forwardHuman Brat ortholog TRIM3 is a tumor suppressor that regulates asymmetric cell division in glioblastoma.Biology of advanced uveal melanoma and next steps for clinical therapeutics.Examining the structure-activity relationship of benzopyran-based inhibitors of the hypoxia inducible factor-1 pathway.Xtalk: a path-based approach for identifying crosstalk between signaling pathwaysDesign and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.PPARγ regulated CIDEA affects pro-apoptotic responses in glioblastoma.Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction.Critical multiple angiogenic factors secreted by glioblastoma stem-like cells underline the need for combinatorial anti-angiogenic therapeutic strategies.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies.Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.Hypoxia inducible factor (HIF) as a model for studying inhibition of protein-protein interactions.Purifying Properly Folded Cysteine-rich, Zinc Finger Containing Recombinant Proteins for Structural Drug Targeting Studies: the CH1 Domain of p300 as a Case Example.A novel small-molecule arylsulfonamide causes energetic stress and suppresses breast and lung tumor growth and metastasis.Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A "structure-activity relationship" perspective.Taking a HIF pill for old age diseases?Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies.
P2860
Q26859355-59DA0857-324F-4D7B-A9FD-DEBB095AF026Q27021749-A8E85150-E84E-4573-9190-D8361A84399FQ27701444-8C7EA4A0-CB01-4E46-80F3-7691329F690EQ28393898-6B169A34-0133-4560-A8EB-C4D280E8F1A3Q28483753-83AEC4F8-97E3-4F52-9ECF-7C7D24BC8CDDQ29248396-C0F60303-9B97-49BA-BE97-B75C484B6B1FQ34052754-C9C85B33-A8F5-4B87-928E-BF0413896BE1Q35079709-A56FE147-0DA6-4429-BCF9-EFD4DE9063A6Q36305521-5C957601-1007-4D80-A5CE-B7D741CA58C4Q37002991-319ADE0D-3716-448B-A5A8-E707C390FF6CQ37130170-45E88B97-0AC7-44B8-9249-F7882C99B834Q37164423-A4E9DBA9-61CD-4A3A-9885-F239B66BEF2DQ37657724-403CDB61-84B6-4873-B9E7-6C0C9D21A08EQ38066416-2BA44CEA-2E66-44D0-BEB4-DD2BE3D8D7EBQ38097867-E0BD77C3-EDA6-48D7-81A1-4D6A4D8DF2D2Q38735845-9D7AE371-B246-4EC4-B22B-F1C32EE61453Q38751306-BC2FAEF4-A1C8-4E11-BB54-8375350E35C1Q38825960-A501E51A-778A-4A42-BD80-34142F11F560Q39573234-F5C86A02-6D67-4B77-AB66-75EAD226A53EQ41559175-1F2348CA-1E66-4978-A03D-C958FD3A8793Q41663058-3EA59594-9BD4-49F7-BACB-B0B98F5DAA63Q47162494-52F5E7B1-ACA7-472D-8803-1E03E9042B9EQ47254418-AEDC53B0-45DA-46B3-BA6A-02E527D4B10AQ51766052-F4F7854B-A7B8-4BC0-93E0-0F4CD09B371BQ55645936-0D9C6316-162F-4ED4-B0E2-390CD62364FE
P2860
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@en
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@nl
type
label
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@en
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@nl
prefLabel
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@en
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@nl
P2093
P2860
P1476
Arylsulfonamide KCN1 inhibits ...... ction with cofactors p300/CBP.
@en
P2093
Adnan A Jabbar
Jeffrey J Olson
Jiyoung Mun
K C Nicolaou
Mark M Goodman
Narra S Devi
Purushotham R Boreddy
Rita G de Noronha
Ruiwen Zhang
Shaoman Yin
P2860
P304
P356
10.1158/1078-0432.CCR-12-0861
P407
P577
2012-08-24T00:00:00Z